NCT06036836: An ongoing trial by Merck Sharp & Dohme LLC
This trial is ongoing. It must report results 2 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06036836 |
|---|---|
| Title | A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Sept. 29, 2023 |
| Completion date | March 9, 2027 |
| Required reporting date | March 8, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |